期刊文献+

去甲氧柔红霉素增强预处理的造血干细胞移植治疗骨髓增生异常综合征及其护理 被引量:1

Idarubicin Enhanced Pretreated Hematopoietic Stem Cell Transplantation in the Treatment of Myelodysplastic Syndrome
暂未订购
导出
摘要 目的探讨去甲氧柔红霉素(IDA)增强预处理方案的外周血造血干细胞移植对骨髓增生异常综合征(MDS)的治疗及护理措施。方法对12例MDS患者施以IDA增强预处理的外周血干细胞移植治疗及护理。结果12例患者均植活成功,显示该预处理方案耐受良好,经过精心的护理,8例患者生存,预期3年总存活率(OS)为66.7%,无病生存率(DFS)为58.3%,2例患者复发。结论 IDA增强预处理的外周血造血干细胞移植,同时辅以正确的护理措施对MDS治疗有效,能降低复发率。 Objective To study the effect of Idarubicin (IDA) on the pretreated peripheral blood hematopoietic stem cell transplantation in the treatment of myelodysplastic syndrome and nursing measures. Methods 12 patients with myelodysplastic syndrome were administered IDA to enhance pretreated peripheral blood stem cell transplantation and nursing. Results all of the 12 cases were engrafted successfully shown that the pretreatment solution tolerated well. With careful nursing,8 patients survived and it was expected that the overall survival (OS) rate was 66.7% ,the disease-free survival rate was 58.3% and 2 cases of patients had a recurrence. Conclusion IDA do increase peripheral blood hematopoietic stem cell transplantation. Meanwhile, taking the correct nursing measures are effective to the treatment of myelodysplastic syndrome,and cocan reduce the recurrence rate.
出处 《成都医学院学报》 CAS 2014年第5期644-647,共4页 Journal of Chengdu Medical College
基金 华中科技大学自助创新研究基金项目(NO:2014QN059) 医院临床学科重点项目(卫规财函[2013]353号)
关键词 去甲氧柔红霉素 异基因外周造血干细胞移植 骨髓增生异常综合征 Enhance pretreatment scheme To methoxyl soft erythromycin Allogeneic peripheral blood stem cell transplantation Myelodysplastic syndrome: Nursing
  • 相关文献

参考文献10

  • 1肖毅,耿哲,张义成,张东华,周剑峰,孙汉英,刘文励.BEAM方案预处理行自体外周血干细胞移植治疗恶性淋巴瘤[J].中国癌症杂志,2008,18(7):526-530. 被引量:6
  • 2周红升,余国攀,张贤,等.中大剂量足叶乙甙增强TBI/CY预处理方案的异基因造血干细胞移植治疗急性淋巴细胞白血病的初步研究[C].中华医学会血液学分会第十一届全国白血病淋巴瘤会议论文集,2011:172-173.
  • 3Menggarelli A, Iorii AP, Guglielmi C, et al. Idarubicin intensified BUCY2 regimen in allogeneic unmanipulted transplant for high-risk hematological malignancies [J ]. Leukemia, 2000,14 (12) : 2052-2058.
  • 4周红升,张东华,黄伟,肖毅,李登举,刘文励.去甲氧柔红霉素增强预处理的造血干细胞移植治疗高危因素的恶性血液疾病[J].中国现代医学杂志,2007,17(2):183-185. 被引量:2
  • 5Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age[J]. Blood,2000,95 (4) : 1188-1194.
  • 6Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneie bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low- risk myelodysplasia is associated with improved nutcome[J]. Blood,2004,104(2) :579-585.
  • 7齐越,杨明珍.去甲氧柔红霉素在急性白血病中的应用[J].医学综述,2013,19(4):696-699. 被引量:9
  • 8肖音,游泳,陈智超,夏凌辉,洪梅,邹萍.增强预处理方案的造血干细胞移植对骨髓增生异常综合征的治疗效果[J].中华器官移植杂志,2010,31(2):75-78. 被引量:1
  • 9Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age[J]. Blood,2013,105(4) : 1810-1814.
  • 10Gupta V, Daly A, Lipton JH, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older[J]. Biology of Blood and Marrow Transplantation, 2010,11 (10) .. 764-772.

二级参考文献16

  • 1张东华,张路,肖毅,黄伟,李登举,冉丹,黄亮,周剑锋,黄梅,孙汉英,刘文励.Clinical Observation of Patients with Hematologic Malignancies Treated with Hematopoietic Stem Cell Transplantation[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2004,24(4):345-349. 被引量:5
  • 2张东华,游世伦,肖毅,黄伟,张路,李登举,冉丹,黄亮.移植物抗宿主病的发生及其早期预测分析[J].中国现代医学杂志,2005,15(9):1339-1342. 被引量:2
  • 3许兰平,刘开彦,陈欢,刘代红,韩伟,陈育红,高志勇,路瑾,王景枝,陆道培,黄晓军.异基因造血干细胞移植治疗骨髓增生异常综合征30例分析[J].中华血液学杂志,2006,27(8):518-521. 被引量:17
  • 4胡亮钉,陈虎,江岷,李渤涛,秦茂权,俞志勇,李欲航.异基因外周血造血干细胞移植治疗骨髓增生异常综合征23例疗效分析[J].中华血液学杂志,2006,27(8):522-524. 被引量:7
  • 5MENGARELLI A, IORI AP, GUGLIELMI C, et al. Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies [J]. Leukemia,2000, 14(12): 2052-2058.
  • 6The AML Collaborative Group. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid[J], leukaemia, 1998, 103(1): 100-109.
  • 7DEANE M, KOH M, FORONI L,et al. FLAG-idarubicin and allogeneie stem cell transplantation for Ph-positive ALL beyond First remission [J]. Bone Marrow Transplant, 1998, 22 (12):1137-1143.
  • 8GARNIER-SUILLEROT A, MARBEUF-GUEYE C, SALERNO M, et al. Analysis of drug transport kinetics in multidrug-resisrant cells: implications for drug action[J]. Curt Med Chem, 2001,8(1): 51-64.
  • 9JERJIS S, ROOVERS E, MUUS P, et al, Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission[J]. Bone Marrow Transplant, 1998, 22(1): 13-19.
  • 10FERRARA F, PALMIERI S, DE SIMONE M, et al. High-dose idarubicin and busulphan as conditioning to autologous stem cell transplantation in adult patients with acute myeloid leukaemia [J].Br J Haematol, 2005, 128(2): 234-241.

共引文献14

同被引文献13

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部